I am a Master of Biomedical student at the University of Melbourne driven by a desire to find better, more permanent solutions for chronic diseases like type 1 diabetes (T1D). My research explores how we can restore the body’s natural ability to produce insulin — moving beyond symptom management to true cellular regeneration. The ultimate goal of my work is to improve the quality of life for millions living with T1D by developing therapies that replace lost insulin-producing β-cells, potentially eliminating the need for lifelong injections.

To achieve this, I focus on epigenetic reprogramming — a technique that uses small molecules to unlock the hidden regenerative potential of cells already present in the human pancreas. My current research investigates how pancreatic ductal epithelial cells and fibroblast-like stellate cells can be converted and interacted together into insulin-producing β-like cells using EZH1/2 inhibitors. These drugs were originally developed for oncology, but we are repurposing them to induce cellular transformation into β-cells.

Inspired by the previous effort from our lab researchers, we use 3D organoid models with Matrigel scaffolding to better mimic the human pancreas and assess cell differentiation through molecular profiling and insulin secretion assays. Our proof-of-concept has shown early promise in 2D systems, and we are now validating insulin functionality in 3D models.

What excites me most about this field is its ability to translate molecular insights into real-world therapies. I believe epigenetic reprogramming holds vast potential — not only for diabetes — but as a broader regenerative strategy in metabolic diseases. Through this work, I hope to contribute to the development of safe, scalable, and clinically impactful therapies that shift the way we treat chronic illness.